J Neurol Surg B Skull Base 2023; 84(01): 051-059
DOI: 10.1055/s-0041-1740968
Original Article

Sinonasal Neuroendocrine Carcinoma: 15 Years of Experience at a Single Institution

1   University of Michigan Medical School, Ann Arbor, Michigan, United States
Kyle K. VanKoevering
2   Division of Skull Base Surgery, Department of Otolaryngology-Head and Neck Surgery, The Ohio State University, Columbus, Ohio, United States
3   Department of Neurosurgery, The Ohio State University, Columbus, Ohio, United States
Jonathan B. McHugh
4   Department of Pathology, Michigan Medicine, Ann Arbor, Michigan, United States
Erin L. McKean
5   Division of Skull Base Surgery and Rhinology, Department of Otolaryngology-Head and Neck Surgery, Michigan Medicine, Ann Arbor, Michigan, United States
6   Department of Neurosurgery, Michigan Medicine, Ann Arbor, Michigan, United States
› Institutsangaben


Objectives Sinonasal neuroendocrine carcinomas (SNECs) are among the rarest paranasal sinus cancers. Consensus guidelines for therapy are difficult to develop due to limited data regarding the natural history and successful treatment of these tumors. This study presents 15 years of experience treating SNEC at a single institution and a review of the literature.

Design Retrospective review.

Setting Academic medical center in the United States.

Participants Patients diagnosed with primary SNEC.

Main Outcome Measures Overall survival.

Results Thirteen patients were identified and included. Overall estimated survival was 74.6% at 5 years. Ten of 13 (76.9%) patients were diagnosed with high-grade neuroendocrine carcinoma and three (23.1%) with intermediate or low grade. All three patients with low- or intermediate-grade cancer survived more than 10 years from their initial diagnosis (median survival: 11.6 years) and are currently alive. The four patients who died had high-grade carcinoma, and estimated overall 5-year survival for all patients with high-grade carcinomas was 65.6%. Five patients, all with high-grade carcinoma, of seven who completed primary chemoradiation therapy (CRT) required salvage resection, and 60% are alive without disease.

Conclusion This cohort has a higher overall rate of survival than many recent case series and reviews. There is consensus that multimodal therapy is preferred over monotherapy, but approaches to treatment vary widely. Our approach of surgical resection as primary therapy for low-grade tumors and primary CRT for high-grade SNEC has been successful, and could indicate hope for improved survival among these patients.


Eingereicht: 20. Oktober 2021

Angenommen: 12. November 2021

Artikel online veröffentlicht:
10. Januar 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • References

  • 1 Silva EG, Butler JJ, Mackay B, Goepfert H. Neuroblastomas and neuroendocrine carcinomas of the nasal cavity: a proposed new classification. Cancer 1982; 50 (11) 2388-2405
  • 2 Frierson Jr HF, Mills SE, Fechner RE, Taxy JB, Levine PA. Sinonasal undifferentiated carcinoma. An aggressive neoplasm derived from schneiderian epithelium and distinct from olfactory neuroblastoma. Am J Surg Pathol 1986; 10 (11) 771-779
  • 3 Bell D, Hanna EY, Weber RS. et al. Neuroendocrine neoplasms of the sinonasal region. Head Neck 2016; 38 (S1): E2259-E2266
  • 4 Choi KY, Amit M, Tam S. et al. Clinical implication of diagnostic and histopathologic discrepancies in sinonasal malignancies. Laryngoscope 2020
  • 5 van der Laan TP, Iepsma R, Witjes MJH, van der Laan BFAM, Plaat BEC, Halmos GB. Meta-analysis of 701 published cases of sinonasal neuroendocrine carcinoma: The importance of differentiation grade in determining treatment strategy. Oral Oncol 2016; 63: 1-9
  • 6 Likhacheva A, Rosenthal DI, Hanna E, Kupferman M, Demonte F, El-Naggar AK. Sinonasal neuroendocrine carcinoma: impact of differentiation status on response and outcome. Head Neck Oncol 2011; 3 (01) 32
  • 7 Rosenthal DI, Barker Jr JL, El-Naggar AK. et al. Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer 2004; 101 (11) 2567-2573
  • 8 Mitchell EH, Diaz A, Yilmaz T. et al. Multimodality treatment for sinonasal neuroendocrine carcinoma. Head Neck 2012; 34 (10) 1372-1376
  • 9 El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ. eds. WHO Classification of Head and Neck Tumours. 4th ed.. International Agency for Research on Cancer; Lyon, France: 2017
  • 10 Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. (editors). AJCC cancer staging manual, 7th edition. France: Springer; 2010
  • 11 Turri-Zanoni M, Maragliano R, Battaglia P. et al. The clinicopathological spectrum of olfactory neuroblastoma and sinonasal neuroendocrine neoplasms: Refinements in diagnostic criteria and impact of multimodal treatments on survival. Oral Oncol 2017; 74: 21-29
  • 12 Patel TD, Vazquez A, Dubal PM, Baredes S, Liu JK, Eloy JA. Sinonasal neuroendocrine carcinoma: a population-based analysis of incidence and survival. Int Forum Allergy Rhinol 2015; 5 (05) 448-453
  • 13 van der Laan TP, Bij HP, van Hemel BM. et al. The importance of multimodality therapy in the treatment of sinonasal neuroendocrine carcinoma. Eur Arch Otorhinolaryngol 2013; 270 (09) 2565-2568
  • 14 Perez-Ordonez B, Caruana SM, Huvos AG, Shah JP. Small cell neuroendocrine carcinoma of the nasal cavity and paranasal sinuses. Hum Pathol 1998; 29 (08) 826-832
  • 15 Faisal M, Haider I, Adeel M, Waqas O, Hussain R, Jamshed A. Small cell neuroendocrine carcinoma of nose and paranasal sinuses: the Shaukat Khanum Memorial Cancer Hospital experience and review of literature. J Pak Med Assoc 2018; 68 (01) 133-136
  • 16 Kuan EC, Alonso JE, Tajudeen BA, Arshi A, Mallen-St Clair J, St John MA. Small cell carcinoma of the head and neck: a comparative study by primary site based on population data. Laryngoscope 2017; 127 (08) 1785-1790
  • 17 VanKoevering KK, Sabetsarvestani K, Sullivan SE, Barkan A, Mierzwa M, McKean EL. Pituitary dysfunction after radiation for anterior skull base malignancies: incidence and screening. J Neurol Surg B Skull Base 2020; 81 (01) 75-81
  • 18 La Rosa S, Furlan D, Franzi F. et al. Mixed exocrine-neuroendocrine carcinoma of the nasal cavity: clinico-pathologic and molecular study of a case and review of the literature. Head Neck Pathol 2013; 7 (01) 76-84
  • 19 López F, Lund VJ, Suárez C. et al. The impact of histologic phenotype in the treatment of sinonasal cancer. Adv Ther 2017; 34 (10) 2181-2198
  • 20 Stueven AK, Kayser A, Wetz C. et al. Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future. Int J Mol Sci 2019; 20 (12) 3049
  • 21 Wang C-P, Hsieh C-Y, Chang Y-L. et al. Postirradiated neuroendocrine carcinoma of the sinonasal tract. Laryngoscope 2008; 118 (05) 804-809
  • 22 Chang C-F, Li W-Y, Shu C-H, Ho C-Y. Sino-nasal neuro-endocrine carcinoma. Acta Otolaryngol 2010; 130 (03) 392-397
  • 23 Austin JR, Cebrun H, Kershisnik MM. et al. Olfactory neuroblastoma and neuroendocrine carcinoma of the anterior skull base: treatment results at the m.d. Anderson cancer center. Skull Base Surg 1996; 6 (01) 1-8